Evaluation of radiation treatment volumes for unknown primaries of the head and neck in the era of FDG PET.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 20 12 2019
accepted: 13 03 2020
entrez: 11 4 2020
pubmed: 11 4 2020
medline: 10 7 2020
Statut: epublish

Résumé

Positron-emission tomography (PET) has improved identification of the primary tumor as well as occult nodal burden in cancer of the head and neck. Nevertheless, there are still patients where the primary tumor cannot be located. In these situations, the standard of care is comprehensive head and neck radiation therapy however it is unclear whether this is necessary. This study examines the effects of radiation treatment volume on outcomes among using data from two cancer centers in unknown primary carcinoma of the head and neck. Patients received unilateral (n = 34), or bilateral radiation (n = 28). Patient factors such as age, gender, smoking history, and patterns of failure were compared using Mann Whitney U and Chi Square. Overall survival (OS) and disease free survival (DFS) trends were estimated using Kaplan-Meier survival curves. Effect of treatment volume on survival was examined using multivariate cox proportional hazard regression model. No significant differences were observed in the frequency of local (p = 0.32), regional (p = 0.50), or distant (p = 0.76) failures between unilateral and bilateral radiation therapy. By Kaplan-Meier estimates, OS (3-year OS bilateral = 71.67%, unilateral = 77.90%, p = 0.50) and DFS (3-year DFS bilateral = 77.92%, unilateral = 69.43%, p = 0.63) were similar between the two treatment approaches. Lastly, multivariate analysis did not demonstrate any significant differences in outcome by treatment volumes (OS: HR = 0.74, 95% CI: 0.31, 1.81, p = 0.51; DFS: HR: 0.68, 95% CI: 0.24, 1.93, p = 0.47). Unilateral radiation therapy compared with bilateral produced similar survival.

Identifiants

pubmed: 32275670
doi: 10.1371/journal.pone.0231042
pii: PONE-D-19-35352
pmc: PMC7147765
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0231042

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD070727
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):797-802
pubmed: 9128954
Radiother Oncol. 1995 Jun;35(3):206-11
pubmed: 7480823
Oncotarget. 2016 Nov 29;7(48):78736-78746
pubmed: 27791201
Radiat Oncol. 2017 May 10;12(1):82
pubmed: 28486947
Radiother Oncol. 2000 May;55(2):121-9
pubmed: 10799723
Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):626-9
pubmed: 16027287
Aust N Z J Surg. 2000 Apr;70(4):263-8
pubmed: 10779057
J Natl Cancer Inst. 2015 Dec 09;107(12):djv344
pubmed: 26656751
Head Neck. 2016 Apr;38(4):578-81
pubmed: 25488125
Head Neck. 2013 May;35(5):684-8
pubmed: 22619040
Radiother Oncol. 2009 Dec;93(3):483-7
pubmed: 19892420
Laryngoscope. 2017 May;127(5):1087-1092
pubmed: 27808409
Tumori. 2009 Mar-Apr;95(2):185-90
pubmed: 19579864
Am J Clin Oncol. 2009 Dec;32(6):587-91
pubmed: 19581794
Crit Rev Oncol Hematol. 2018 Oct;130:51-59
pubmed: 30196912
Head Neck. 2019 Jun;41(6):1785-1794
pubmed: 30659688
World J Clin Oncol. 2012 Apr 10;3(4):57-62
pubmed: 22553505
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1051-8
pubmed: 17716824
Head Neck. 2013 Jan;35(1):123-32
pubmed: 22034046
Arch Otolaryngol Head Neck Surg. 2012 Jul;138(7):656-61
pubmed: 22801890
Strahlenther Onkol. 2012 Jan;188(1):56-61
pubmed: 22189437
Laryngoscope. 2016 Jun;126(6):1354-8
pubmed: 26671043
J Clin Virol. 2016 Dec;85:22-26
pubmed: 27816020

Auteurs

Alexis Platek (A)

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, United States of America.

Michael Mix (M)

Department of Radiation Oncology, Upstate Medical University, Syracuse, NY, United States of America.

Varun Chowdhry (V)

Roswell Park Comprehensive Cancer Center, Department of Radiation Medicine, Buffalo, NY, United States of America.

Mark Farrugia (M)

Roswell Park Comprehensive Cancer Center, Department of Radiation Medicine, Buffalo, NY, United States of America.

Michael A Lacombe (MA)

Department of Radiation Oncology, Upstate Medical University, Syracuse, NY, United States of America.

Jeffrey A Bogart (JA)

Department of Radiation Oncology, Upstate Medical University, Syracuse, NY, United States of America.

Luke Degraaf (L)

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, United States of America.

Austin Iovoli (A)

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, United States of America.

Hassan Arshad (H)

Roswell Park Comprehensive Cancer Center, Department of Head and Neck/Plastic and Reconstructive Surgery, Buffalo, NY, United States of America.

Kimberly Wooten (K)

Roswell Park Comprehensive Cancer Center, Department of Head and Neck/Plastic and Reconstructive Surgery, Buffalo, NY, United States of America.

Vishal Gupta (V)

Roswell Park Comprehensive Cancer Center, Department of Head and Neck/Plastic and Reconstructive Surgery, Buffalo, NY, United States of America.

Wesley L Hicks (WL)

Roswell Park Comprehensive Cancer Center, Department of Head and Neck/Plastic and Reconstructive Surgery, Buffalo, NY, United States of America.

Mary E Platek (ME)

Roswell Park Comprehensive Cancer Center, Department of Biostatistics, Buffalo, New York, United States of America.
Department of Dietetics, D'Youville College, Buffalo, New York, United States of America.

Seung S Hahn (SS)

Department of Radiation Oncology, Upstate Medical University, Syracuse, NY, United States of America.

Anurag K Singh (AK)

Roswell Park Comprehensive Cancer Center, Department of Radiation Medicine, Buffalo, NY, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH